18.Brankston GN, et al. Am J Obstet Gynecol 2004;190:188 19.Tuffnell DJ et al.In The Cochrane Library, Issue 3, 2004. Chichester,UK:John Wiley & Sons,Ltd. 20.Yki-Jarvinen H. N Engl J Med 2004;351:1106 21.Woerle HJ et al. Arch Intern Med 2004; 164:1627-1632 22.Selvin E et al.Ann Intern Med 2004; 141:421-431 23.Khaw K-T et al.Ann Intern Med 2004; 141:413-420 24. Clinical Evidence Edizione Italiana; 2001:276 25.Fung TT et al. Arch Intern Med. 2004;164:2235-2240 26.Brown LC et al. CMAJ 2004; 171:1189-1192 27.Drug and Therapeutics Bulletin, Ed italiana. 2004:77-80. 28.Davidson MB. Starting insulin therapy in type 2 diabetic patients: Does it really matter how? Diabetes Care 2005 Feb; 28:494-5 29.Roeckl-Wiedmann I et al. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg January 2005;92:24-32 30. Crowther Ca et al. for the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes.N Engl J Med 2005 Jun 16; 352: 2477-2486 31.Dormandy JA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366:1279-1289. 32. Nissen SE et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005 Nov 23; 294:2581-2586 33.Casas JP et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 Dec 10; 366: 2026-2033.
|
|
